Additional expression of T-cell engager in clinically tested oncolytic adeno-immunotherapy redirects tumor-infiltrated, irrelevant T cells against cancer cells to enhance antitumor immunity

Additional expression of T-cell engager in clinically tested oncolytic adeno-immunotherapy redirects tumor-infiltrated, irrelevant T cells against cancer cells to enhance antitumor immunity

Background Oncolytic adenoviruses (OAds) are the most clinically tested viral vectors for solid tumors. However, most clinically tested “Armed” OAds show limited antitumor effects in patients with various solid tumors even with increased dosages and multiple injections. We developed a binary oncolyt...

Full description

Saved in:
Bibliographic Details
Main Authors: Bora Lim, Caroline Porter, Mae Woods, Masataka Suzuki, Daisuke Morita, Amanda Rosewell Shaw, Greyson Biegert, Spyridoula Vasileiou
Format: Article
Language:English
Published: BMJ Publishing Group 2024-12-01
Series:Journal for ImmunoTherapy of Cancer
Online Access:https://jitc.bmj.com/content/12/12/e009741.full
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items